SCHEMBL4686137

SCHEMBL4686137

O=C(COc1ccc2ncccc2c1)N1CCN(c2ccc(-c3cc(CNc4ccon4)on3)cc2F)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.40
LMNA P02545 5/20 0.40
ALDH1A1 P00352 5/20 0.40
MAPT P10636 10/20 0.40
KDM4E B2RXH2 2/20 0.40
RAB9A P51151 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
GAA P10253 2/20 0.39
ALOX15 P16050 1/20 0.39
HTT P42858 3/20 0.39
MAPK1 P28482 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TNF P01375 1/20 0.37
NOD1 Q9Y239 1/20 0.37
PPARG P37231 1/20 0.37
NR2E3 Q9Y5X4 1/20 0.37
NCOR2 Q9Y618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4784687 0.88 SMN1; SMN2 (0.45) SMN1; SMN2LMNAALDH1A1MAPTKDM4E
SCHEMBL4686134 0.84 MAPT (0.40) SMN1; SMN2LMNAALDH1A1MAPTKDM4E
SCHEMBL4682699 0.81 GAA (0.38) SMN1; SMN2LMNAALDH1A1MAPTL3MBTL1
SCHEMBL1383599 0.79 GFER (0.38) SMN1; SMN2LMNAALDH1A1MAPTGAA
SCHEMBL4683309 0.77 ALDH1A1 (0.42) SMN1; SMN2LMNAALDH1A1MAPTKDM4E
SCHEMBL4684254 0.76 ALDH1A1 (0.40) LMNAALDH1A1MAPTGAAKMT2A
SCHEMBL4678388 0.74 KDM4E (0.36) SMN1; SMN2ALDH1A1KDM4EMAPK1HSD17B10
SCHEMBL3591482 0.73 IGF1R (0.40) KDRSYK
SCHEMBL6400646 0.72 KDM4E (0.35) SMN1; SMN2ALDH1A1MAPTKDM4EGAA
SCHEMBL4787570 0.72 ALDH1A1 (0.40) SMN1; SMN2LMNAALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1437349-B9 SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS S A L V A T LAB SA (ES) 2008-09-10 EP disclosed
EP-1437349-B1 SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS S A L V A T LAB SA (ES) 2007-08-15 EP disclosed
US-20050014806-A1 Substituted isoxazoles and their use as antibiotics LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2005-01-20 US disclosed
EP-1437349-A1 SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2004-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014806-A1 Substituted isoxazoles and their use as antibiotics XDH, SCO2, HAX1 SMN1; SMN2 3326/4885LMNA 2423/4885ALDH1A1 1181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.